Stockysis — AI-Powered Stock News & Sentiment Analysis

HC Wainwright & Co. Maintains Buy on BridgeBio Oncology, Raises Price Target to $29

Benzinga Newsdesk www.benzinga.com Positive 72.5%

Neg 0% Neu 0% Pos 72.5%

HC Wainwright & Co. analyst Robert Burns maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and raises the price target from $27 to $29.

Comments

No comments yet. Be the first!